November 5, 2018

Received TFDA Approval to Conduct Phase Ib/IIa Clinical Trial: "A Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Potential Efficacy of AD17002-AI in Subjects with House Dust Mite-Induced Allergic Rhinitis."